Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Scleroderma lung: pathogenesis, evaluation, and current therapy.

H T Co¹, J A Block, W Sequeira

¹Section of Rheumatology, Rush Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA.

American Journal of Therapeutics

|April 24, 2001

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Thirty years of publishing osteoarthritis research in perspective - a special journal issue to mark the 30th anniversary of Osteoarthritis and Cartilage.

Osteoarthritis and cartilage·2023

Same author

The Fundamentals of OA.

Osteoarthritis and cartilage·2021

Same author

The plain language summary (Lay Language Summary) in Osteoarthritis and Cartilage.

Osteoarthritis and cartilage·2021

Same author

The reproducibility crisis and statistical review of clinical and translational studies.

Osteoarthritis and cartilage·2021

Same author

Psychometric properties of MDHAQ/RAPID3 in patients with systemic lupus erythematosus.

Lupus·2018

Same author

Validation of the LupusPRO version 1.8: an update to a disease-specific patient-reported outcome tool for systemic lupus erythematosus.

Lupus·2017

Same journal

Abrocitinib as a Novel Therapeutic Option for Elastolytic Giant Cell Granuloma: A Case Report.

American journal of therapeutics·2026

Same journal

Dupilumab for Lichen Amyloidosis in an Elderly Multimorbid Patient.

American journal of therapeutics·2026

Same journal

Deucravacitinib for Generalized Pustular Psoriasis and Comorbid Polymyositis: Dual Efficacy and Favorable Safety.

American journal of therapeutics·2026

Same journal

Repurposed Drugs and Cardiovascular Morbidity: A Cost-Effectiveness Analysis.

American journal of therapeutics·2026

Same journal

Do Not Treat a Sequencing Report: Therapeutic Stewardship in Endometrial Microbiome Testing.

American journal of therapeutics·2026

Same journal

Right Side Accessory Pathway Mediated Cardiomyopathy Treated with Amiodarone: First Adult Case Report.

American journal of therapeutics·2026

See all related articles

Interstitial lung disease (ILD) is a leading cause of death in scleroderma. Early detection and treatment, potentially with cyclophosphamide and prednisone, may improve outcomes before lung fibrosis develops.

Area of Science:

Rheumatology
Pulmonology
Immunology

Background:

Interstitial lung disease (ILD) is the primary cause of mortality in patients with scleroderma.
The underlying pathogenesis of ILD in scleroderma remains incompletely understood.
Early detection and intervention are crucial to prevent irreversible lung fibrosis.

Observation:

Uncontrolled studies suggest a potential benefit from combining daily oral cyclophosphamide with low-dose prednisone.
This combination therapy aims to manage ILD in scleroderma patients.
Further research is needed to validate these preliminary findings.

Findings:

The combination of cyclophosphamide and prednisone shows promise in managing scleroderma-associated ILD.
Evidence from uncontrolled studies indicates potential efficacy.

Related Experiment Videos

Conclusions require confirmation through rigorous clinical trials.

Implications:

Effective management of ILD could significantly reduce mortality in scleroderma patients.
Early treatment strategies may halt or slow the progression of lung fibrosis.
Further investigation is warranted to establish definitive treatment guidelines for this serious complication.